Showing 2331-2340 of 3315 results for "".
- Report: More Than Half of All Age-Related Macular Degeneration Cases Go Undiagnosedhttps://modernod.com/news/report-more-than-half-of-all-age-related-macular-degeneration-cases-go-undiagnosed/2477776/In the nine major pharmaceutical markets, less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years and older, according to analytics company GlobalData. The company’s latest report, ‘
- COVID-19: Updates From Society Leadershiphttps://modernod.com/news/covid-19-updates-from-society-leadership/2477712/
- SightGlass Vision Announces R&D Webinar Featuring Leading Myopia Expertshttps://modernod.com/news/sightglass-vision-announces-rd-webinar-featuring-leading-myopia-experts/2477704/SightGlass Vision announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the company’s novel glasses designed to slow the progression of myopia in chil
- In Race for a Coronavirus Vaccine, an Oxford Group Leaps Aheadhttps://modernod.com/news/in-race-for-a-coronavirus-vaccine-an-oxford-group-leaps-ahead/2477663/In the worldwide race for a vaccine to stop the coronavirus, the laboratory sprinting fastest is at Oxford University, according to a
- Market Scope: COVID-19 Fallout Could Reshape Ophthalmology in Indiahttps://modernod.com/news/market-scope-covid-19-fallout-could-reshape-ophthalmology-in-india/2477647/Market Scope estimates the total ophthalmic market in India in 2020 at $1.3 billion, with an optimistic assumption that the COVID-19 suspension of elective surgeries will last for 2 months or less. The firms forecasts a rapid return to 2019 levels of activity, resulting in an overall 25 percent r
- WHO Accidently Leaks Disappointing Results of Chinese Clinical Trial Testing Gilead’s Remdesivir in Severe COVID-19https://modernod.com/news/who-accidently-leaks-disappointing-results-of-chinese-clinical-trial-testing-gileads-remdesivir-in-severe-covid-19/2477645/According to a draft document published in error by the World Health Organization (WHO), Gilead Sciences’ remdesivir failed to improve the condition of patients with severe COVID-19 participating in a Chinese clinical trial, nor was the drug found to reduce the virus’ presence in the
- Telemedicine: Watch and Learnhttps://modernod.com/news/telemedicine-watch-and-learn/2477587/
- Retina Business Leaders Discuss How to Manage Financial Consequences of COVID-19https://modernod.com/news/retina-business-leaders-discuss-how-to-manage-covid-19s-financial-consequences/2477573/On a recent episode of New Retina Radio, John Kit
- Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19https://modernod.com/news/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19/2477489/Johnson & Johnson announced a $1 billion deal with the U.S. government to create enough manufacturing capacity to make more than 1 billion doses of a potential vaccine for COVID-19. Johnson & Johnson said on Monday it has been working on a vaccine since January 2020 and expects to initiat
- US ECPs’ Business Concerns and Stress Levels Grow, as Coronavirus Pandemic Impact Widenshttps://modernod.com/news/us-ecps-business-concerns-and-stress-levels-grow-as-coronavirus-pandemic-impact-widens/2477464/As the number of COVID-19 cases grow and more parts of the U.S. put “shelter-in-place” requests and mandates into place due to the coronavirus pandemic, the impact is growing more pronounced in the provider sector of business, according to a VisionMonday